DELCATH SYSTEMS, INC.

Delcath Systems' stockholders approved an amendment to the 2020 Omnibus Equity Incentive Plan, increasing the number of shares available by 1,800,000. Additionally, stockholders elected Elizabeth Czerepak and John R. Sylvester as Class II directors, ratified CBIZ CPAs P.C. as the independent auditor for fiscal year 2026, and approved a non-binding advisory vote on executive compensation. Approximately 67.44% of eligible shares were represented at the Annual Meeting.

Delcath Systems reported a net loss of $(1.07) million for the first quarter of 2026, a shift from a net income of $1.07 million in the prior year period. Despite the loss, product revenue increased by 26.3% to $25.0 million. The company continues to advance its clinical development programs for HEPZATO, with Phase 2 trials for metastatic colorectal cancer and metastatic breast cancer progressing, and also repurchased $3.0 million of common stock during the quarter.

Delcath Systems reported first-quarter 2026 financial results, with total revenue increasing to $25.0 million from $19.8 million year-over-year, driven by strong HEPZATO KIT sales. Despite revenue growth, the company posted a net loss of $1.1 million compared to a net income in the prior year, and adjusted EBITDA declined. The company reaffirmed its full-year 2026 revenue guidance of at least $100 million and highlighted significant HEPZATO volume growth and positive clinical trial publication.